Research programme: peptide antibacterials - Bayer

Drug Profile

Research programme: peptide antibacterials - Bayer

Alternative Names: Peptide antibacterials research programme - Bayer; Research programme: TAN 1057 analogues - Bayer AG; TAN 1057 analogues research programme - Bayer AG

Latest Information Update: 25 Mar 2010

Price : $50

At a glance

  • Originator Bayer
  • Class Dipeptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Gram-positive infections

Most Recent Events

  • 18 Sep 2002 Preclinical trials in Gram-positive infections in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top